MacroGenics Q1 2020 Earnings Report
Key Takeaways
MacroGenics reported total revenue of $13.7 million for the quarter ended March 31, 2020, compared to $9.7 million for the quarter ended March 31, 2019. Research and development expenses were $48.9 million, and net loss was $44.7 million.
Observed progress and clinical activity across a broad portfolio of seven antibody-based product candidates.
Anticipate presenting clinical data from all molecules this year.
Expect some near-term impact on clinical trial site initiation and patient enrollment due to COVID-19 pandemic.
Reiterated guidance for the timing of anticipated 2020 clinical data read-outs or regulatory events.
MacroGenics
MacroGenics
MacroGenics Revenue by Segment
Forward Guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities as of March 31, 2020, combined with anticipated and potential collaboration payments, should enable it to fund its operations into 2022, assuming the Company's programs and collaborations advance as currently contemplated.